300347 Stock Overview
Provides contract research organization services in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥61.33 |
| 52 Week High | CN¥82.79 |
| 52 Week Low | CN¥36.12 |
| Beta | 0.85 |
| 11 Month Change | -8.79% |
| 3 Month Change | 28.82% |
| 1 Year Change | -3.36% |
| 33 Year Change | -56.50% |
| 5 Year Change | -2.34% |
| Change since IPO | 225.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300347 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -1.7% | -4.4% | -2.1% |
| 1Y | -3.4% | -32.3% | 2.8% |
Return vs Industry: 300347 exceeded the CN Life Sciences industry which returned -29.5% over the past year.
Return vs Market: 300347 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 300347 volatility | |
|---|---|
| 300347 Average Weekly Movement | 10.6% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300347's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300347's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,348 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
| 300347 fundamental statistics | |
|---|---|
| Market cap | CN¥48.98b |
| Earnings (TTM) | CN¥958.67m |
| Revenue (TTM) | CN¥6.80b |
55.1x
P/E Ratio7.8x
P/S RatioIs 300347 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300347 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.80b |
| Cost of Revenue | CN¥4.27b |
| Gross Profit | CN¥2.54b |
| Other Expenses | CN¥1.58b |
| Earnings | CN¥958.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.11 |
| Gross Margin | 37.29% |
| Net Profit Margin | 14.10% |
| Debt/Equity Ratio | 15.2% |
How did 300347 perform over the long term?
See historical performance and comparison